Ian A.J. Lorimer

1.9k total citations
41 papers, 1.3k citations indexed

About

Ian A.J. Lorimer is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Ian A.J. Lorimer has authored 41 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 17 papers in Oncology and 9 papers in Cancer Research. Recurrent topics in Ian A.J. Lorimer's work include Protein Kinase Regulation and GTPase Signaling (7 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Ian A.J. Lorimer is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (7 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Ian A.J. Lorimer collaborates with scholars based in Canada, United States and Australia. Ian A.J. Lorimer's co-authors include D A E Parolin, Jim Dimitroulakos, Glenwood D. Goss, R. Mitchell Baldwin, Jennifer Hanson, Manijeh Daneshmand, B. D. Sanwal, Aleksandra Franovic, Lakshman Gunaratnam and Eijiro Nakamura and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Ian A.J. Lorimer

41 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ian A.J. Lorimer Canada 21 710 518 399 308 134 41 1.3k
Eiwa Ishida Japan 24 930 1.3× 356 0.7× 297 0.7× 260 0.8× 166 1.2× 52 1.4k
Emmanuel Martínez-Ledesma United States 14 1.0k 1.4× 341 0.7× 460 1.2× 314 1.0× 204 1.5× 34 1.6k
Keltouma Driouch France 24 1.3k 1.8× 687 1.3× 425 1.1× 264 0.9× 73 0.5× 41 1.8k
Janni Mirosevich United States 12 866 1.2× 342 0.7× 236 0.6× 626 2.0× 100 0.7× 18 1.4k
Shaoyan Xi China 20 540 0.8× 298 0.6× 330 0.8× 179 0.6× 137 1.0× 60 1.1k
Ciara Metcalfe United States 14 1.1k 1.5× 588 1.1× 197 0.5× 196 0.6× 88 0.7× 33 1.6k
Anna L. Stratford Canada 24 1.2k 1.7× 567 1.1× 445 1.1× 130 0.4× 96 0.7× 27 1.9k
Matthew T. Harbison United States 8 853 1.2× 924 1.8× 362 0.9× 275 0.9× 60 0.4× 8 1.6k
Rajani Kanteti United States 21 761 1.1× 513 1.0× 219 0.5× 446 1.4× 51 0.4× 40 1.4k

Countries citing papers authored by Ian A.J. Lorimer

Since Specialization
Citations

This map shows the geographic impact of Ian A.J. Lorimer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian A.J. Lorimer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian A.J. Lorimer more than expected).

Fields of papers citing papers by Ian A.J. Lorimer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian A.J. Lorimer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian A.J. Lorimer. The network helps show where Ian A.J. Lorimer may publish in the future.

Co-authorship network of co-authors of Ian A.J. Lorimer

This figure shows the co-authorship network connecting the top 25 collaborators of Ian A.J. Lorimer. A scholar is included among the top collaborators of Ian A.J. Lorimer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian A.J. Lorimer. Ian A.J. Lorimer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Muñoz, David G., et al.. (2025). Transglutaminase 2 function in glioblastoma tumor efferocytosis. Cell Death and Disease. 16(1). 487–487. 1 indexed citations
2.
Lorimer, Ian A.J.. (2024). Potential roles for efferocytosis in glioblastoma immune evasion. Neuro-Oncology Advances. 6(1). vdae012–vdae012. 2 indexed citations
3.
Wong, Boaz, Daniel Serrano, Zaid Taha, et al.. (2023). Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy. Molecular Therapy. 31(11). 3176–3192. 11 indexed citations
4.
Lorimer, Ian A.J., et al.. (2021). Engineered cells as glioblastoma therapeutics. Cancer Gene Therapy. 29(2). 156–166. 12 indexed citations
5.
Jardine, Karen, et al.. (2021). Identification of Rac guanine nucleotide exchange factors promoting Lgl1 phosphorylation in glioblastoma. Journal of Biological Chemistry. 297(5). 101172–101172. 1 indexed citations
6.
Julian, Lisa M., et al.. (2017). Engineering PTEN-L for Cell-Mediated Delivery. Molecular Therapy — Methods & Clinical Development. 9. 12–22. 11 indexed citations
7.
Jahani‐Asl, Arezu, Hang Yin, Vahab D. Soleimani, et al.. (2016). Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nature Neuroscience. 19(6). 798–806. 74 indexed citations
8.
Karapetis, Christos S., Derek J. Jonker, Manijeh Daneshmand, et al.. (2013). PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17. Clinical Cancer Research. 20(3). 744–753. 128 indexed citations
9.
Jonker, Derek J., Christos S. Karapetis, Christopher J. O’Callaghan, et al.. (2012). BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17.. Journal of Clinical Oncology. 30(15_suppl). 3515–3515. 2 indexed citations
10.
Restall, Ian J. & Ian A.J. Lorimer. (2010). Induction of Premature Senescence by Hsp90 Inhibition in Small Cell Lung Cancer. PLoS ONE. 5(6). e11076–e11076. 20 indexed citations
11.
Baldwin, R. Mitchell, et al.. (2010). Coordination of glioblastoma cell motility by PKCι. Molecular Cancer. 9(1). 233–233. 20 indexed citations
12.
Baldwin, R. Mitchell, et al.. (2008). Activation of p38MAPK Contributes to Expanded Polyglutamine-Induced Cytotoxicity. PLoS ONE. 3(5). e2130–e2130. 11 indexed citations
13.
Zhao, Tong, et al.. (2008). Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. Journal of Neuro-Oncology. 90(1). 9–17. 54 indexed citations
14.
Baldwin, R. Mitchell, D A E Parolin, & Ian A.J. Lorimer. (2008). Regulation of glioblastoma cell invasion by PKCι and RhoB. Oncogene. 27(25). 3587–3595. 47 indexed citations
15.
Baldwin, R. Mitchell, et al.. (2005). Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Cι-mediated attenuation of p38 MAP kinase signaling. Oncogene. 25(20). 2909–2919. 55 indexed citations
16.
MacKenzie, Mary J., Holger W. Hirte, Rakesh Goel, et al.. (2005). A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Investigational New Drugs. 23(2). 165–170. 56 indexed citations
17.
Niknejad, Nima, et al.. (2003). Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells. Journal of Cancer Research and Clinical Oncology. 129(11). 631–641. 28 indexed citations
18.
Lorimer, Ian A.J.. (2002). Mutant Epidermal Growth Factor Receptors as Targets for Cancer Therapy. Current Cancer Drug Targets. 2(2). 91–102. 56 indexed citations
19.
Lorimer, Ian A.J., et al.. (2001). Activation of extracellular-regulated kinases by normal and mutant EGF receptors. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1538(1). 1–9. 40 indexed citations
20.
Lorimer, Ian A.J. & B. D. Sanwal. (1989). Regulation of cyclic AMP-dependent protein kinase levels during skeletal myogenesis. Biochemical Journal. 264(1). 305–308. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eiwa Ishida Breakdown of academic impact, for papers by Emmanuel Martínez-Ledesma Breakdown of academic impact, for papers by Keltouma Driouch Breakdown of academic impact, for papers by Janni Mirosevich Breakdown of academic impact, for papers by Shaoyan Xi Breakdown of academic impact, for papers by Ciara Metcalfe Breakdown of academic impact, for papers by Anna L. Stratford Breakdown of academic impact, for papers by Matthew T. Harbison Breakdown of academic impact, for papers by Rajani Kanteti
Rankless by CCL
2026